Illumina Gets $5.7B Hostile Bid From Roche

San Diego-based Illumina, the maker of genetic analyis equipment and tools for the life sciences industry, said late Tuesday evening that it has received an unsolicited, acquisition proposal from Roche. Roche offered to acquire Illumina for $44.50 per share in cash, or roughly $5.7 billion. Illumina said it has retailed Goldman, Sachs & Co. and Bank of America Merrill Lynch as financial advisors, and Dewey & LeBoeuf LLP as legal advisor to review the proposal.